1.     Kiris I., Karayel-Basar M., Gurel B., Coskun J., Baykal A.T. Proteomic alterations in the cerebellum and hippocampus in an Alzheimer’s disease mouse model: Alleviating effect of palmatine. Biomed. Pharmacother., 2023, 158, 114111. DOI: 10.1016/j.biopha.2022.114111, WOS: 000904404200002

2.     Koca S., Kiris I., Sahin S., Cinar N., Karsidag S., Hanagasi H.A., Yildiz G.B., Baykal A.T. Decreased levels of cytokines implicate altered immune response in plasma of moderate-stage Alzheimer’s disease patients. Neurosci. Lett., 2022, 786, 136799. DOI: 10.1016/j.neulet.2022.136799, WOS:000861069100006

3.     Karayel-Basar M., Uras I., Kiris I., Sahin B., Akgun E., Baykal AT. Spatial Proteomic Alterations Detected Via MALDI-MS Imaging Implicate Neuronal Loss in a Huntington's disease Mouse (YAC128) Brain. Mol. Omics, 2022, 2515- 4184. DOI: 10.1039/d1mo00440a, WOS:000751962600001

4.     Kiris I., Skalicka-Wozniak K., Karayel Basar M., Sahin B., Gurel B., Baykal A.T. Molecular Effects of Pteryxin and Scopoletin in the 5xFAD Alzheimer's Disease Mouse Model. Curr. Med. Chem., 2022, 0929-8673, 29, 16, 2937 - 2950. DOI: 10.2174/0929867328666210827152914, WOS:000823426500008

5.     Kiris I., Karayel Basar M., Sahin B., Gurel B., Coskun J., Mroczek T., Baykal A.T. Evaluation of the Therapeutic Effect of Lycoramine on Alzheimer's Disease in Mouse Model. Curr. Med. Chem., 2021, 0929-8673, 28, 17, 3449-3473. DOI: 10.2174/0929867327999201116193126, WOS:000672743900008

6.     Altinoz M.A., Ucal Y., Yilmaz M.C., Kiris I., Ozisik O., Sezerman U., Ozpinar A., Elmaci I. Progesterone at high doses reduces the growth of U87 and A172 glioblastoma cells: Proteomic changes regarding metabolism and immunity. Cancer Med., 2020, 2045-7634. DOI: 10.1002/cam4.3223, WOS:000543244000001